Matching articles for "brexanolone"
Zuranolone (Zurzuvae) – An Oral Drug for Postpartum Depression
The Medical Letter on Drugs and Therapeutics • December 25, 2023; (Issue 1692)
The FDA has approved the oral GABAA receptor
modulator zuranolone (Zurzuvae – Sage Therapeutics/Biogen) for treatment of postpartum depression
(PPD). Zuranolone is the second drug to be approved
for this...
The FDA has approved the oral GABAA receptor
modulator zuranolone (Zurzuvae – Sage Therapeutics/Biogen) for treatment of postpartum depression
(PPD). Zuranolone is the second drug to be approved
for this indication; brexanolone (Zulresso), another
GABAA receptor modulator, was approved for IV
treatment of PPD in 2019.
Drugs for Depression
The Medical Letter on Drugs and Therapeutics • December 11, 2023; (Issue 1691)
A selective serotonin reuptake inhibitor (SSRI) is
generally used for initial treatment of major depressive
disorder (MDD). A serotonin-norepinephrine reuptake
inhibitor (SNRI), bupropion (Wellbutrin SR,...
A selective serotonin reuptake inhibitor (SSRI) is
generally used for initial treatment of major depressive
disorder (MDD). A serotonin-norepinephrine reuptake
inhibitor (SNRI), bupropion (Wellbutrin SR, and
others), and mirtazapine (Remeron, and others) are
reasonable alternatives. Improvement in symptoms
can occur within the first two weeks of treatment
with these drugs, but a substantial benefit may not be
achieved for 4-8 weeks.
Drugs for Depression
The Medical Letter on Drugs and Therapeutics • February 24, 2020; (Issue 1592)
Complete remission of symptoms is the goal of
treatment for major depressive disorder; a partial
response is associated with an increased risk of
relapse. Improvement in symptoms can occur within
the first...
Complete remission of symptoms is the goal of
treatment for major depressive disorder; a partial
response is associated with an increased risk of
relapse. Improvement in symptoms can occur within
the first two weeks of treatment with an antidepressant,
but it may take 4-8 weeks to achieve a substantial
benefit. Following successful treatment of a first major
depressive episode, antidepressant treatment should
be continued at the same dose for at least 4-9 months
to consolidate recovery. In patients with recurrent
depressive episodes, long-term maintenance treatment
can reduce the risk of relapse.
Brexanolone (Zulresso) for Postpartum Depression
The Medical Letter on Drugs and Therapeutics • May 6, 2019; (Issue 1571)
The FDA has approved the GABAA receptor modulator
brexanolone (Zulresso – Sage Therapeutics) for
IV treatment of postpartum depression (PPD).
Brexanolone is the first drug to be approved by the FDA
for...
The FDA has approved the GABAA receptor modulator
brexanolone (Zulresso – Sage Therapeutics) for
IV treatment of postpartum depression (PPD).
Brexanolone is the first drug to be approved by the FDA
for this indication.